'Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- And Prostate Cancer' Provides a Framework and a Careful Evaluation of Drug Candidates, Technologies and Competitors.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c79346) has announced the addition of Triple Analysis: Antibody Drug Target Atlas in Oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. and Special Focus on Breast- and Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. to their offering. In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. There are currently more than 400 antibody based drugs in development for the treatment of cancer. The author has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care supportive care, n medical and other interventions that attempt to support and make comfortable rather than to cure. . Drug targets and their associated antibodies have been analyzed by the author according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. : - 34 Different molecular functions of target - 13 Major signaling pathways - Cancer stem cells Cancer stem cell hypothesis states that tumors arise from cells termed cancer stem cells that have properties of adult stem cells, particularly the abilities to self-renew and differentiate into multiple cell types, and that these cells persist in tumors as a distinct population - Conjugated conjugated adj. Conjugate. estrogens, conjugated Warning - Hazardous drug! C.E.S. antibodies - Therapeutic effects: Anti-angiogenesis, Apoptosis apoptosis or programmed cell death Mechanism that allows cells to self-destruct when stimulated by the appropriate trigger. It may be initiated when a cell is no longer needed, when a cell becomes a threat to the organism's health, or for other reasons. and Protein Kinase protein kinase /pro·tein ki·nase/ (pro´ten ki´nas) an enzyme that catalyzes the phosphorylation of serine, threonine, or tyrosine groups in enzymes or other proteins, using ATP as a phosphate donor. Inhibition - 31 Targeted cancer indications - Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures - Antibody therapeutic companies In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors A protein kinase inhibitor is a type of enzyme inhibitor which specifically blocks the action of protein kinase. Kinase inhibitors such as dasatinib are sometimes used in the treatment of cancer. and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress. In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements. Breast and Prostate Cancer Highlights - Thorough examination of status and impact of several novel drugs in development - Discussion of the challenges in current and future treatment strategies - Anticancer anticancer, n a medicine or substance used to treat cancer. pipeline of most companies in the field Key reasons to read this report - This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies. - Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. in breast- and prostate cancer R&D, and the results of clinical trials to date. - Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy. Content Outline: 1 Executive Summary 2 Methodologies 3 Table of Contents 4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting? 5 Antibody Drug Targets by Molecular Function 6 Antibody Drugs Targeting Signaling Pathways 7 Antibodies Targeting Cancer Stem Cells 8 Targets of Antibody Conjugates 9 Antibody Drug Targets by Three Major Non Immunological immunologic, immunological emanating from or pertaining to immunology. immunologic competence see immunocompetence. immunologic domains Therapeutic Effects 10 Antibody Targets and Drugs by Cancer Indications 11 Expression Profiles of Antibody Drug Targets 12 Breast Cancer: An Introduction 13 Current Treatment Strategies of Breast cancer 14 Progress in Current Breast Cancer Treatment This article or section recently underwent a major revision or rewrite and needs further review. You can help! The mainstay of breast cancer treatment is surgery when the tumor is localized, with possible adjuvant hormonal therapy (with tamoxifen or an aromatase Strategies 15 Key Therapeutic Strategies for Future Breast Cancer Therapies 16 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline 17 Current Drug Development for Breast Cancer: The Early Stage Pipeline 18 Prostate Cancer: An Introduction 19 Current Prostate Cancer Treatment Strategies 20 Progress in Current Prostate Cancer Treatment Strategies 21 Key Therapeutic Strategies for Future Prostate Cancer Therapies 22 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline 23 Current Prostate Cancer Drug Development: The Early Stage Pipeline 24 Disclaimer 25 Drug Index 26 Company Index 27 Appendix I: Antibody Targets by Companies 3.1 List of Figures 3.2 List of Tables 3.3 List of Boxes For more information visit http://www.researchandmarkets.com/reports/c79346. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion